FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
pharmaceutical-investing Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131
pharmaceutical-investing Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
pharmaceutical-investing Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
pharmaceutical-investing Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma
